Tobramycin

# Tobramycin ## Overview - **Classification**: Aminoglycoside antibiotic - **Mechanism**: Binds irreversibly to the 30S ribosomal subunit, inhibiting bacterial protein synthesis. This leads to misreading of mRNA and bacterial cell death (bactericidal). ## Primary Indications 1. **Systemic Infections**: Treatment of severe Gram-negative bacterial infections (e.g., _Pseudomonas aeruginosa_, _Klebsiella_ spp., _Enterobacter_ spp.). 2. **Cystic Fibrosis Pulmonary Exacerbations**: Management of chronic _P. aeruginosa_ infections in patients with cystic fibrosis (CF). 3. **Ocular Infections**: Treatment of superficial bacterial eye infections (e.g., conjunctivitis, keratitis). ## Adult Dosing ### Systemic Infections (IV/IM) **Severe Systemic Infections (e.g., Sepsis, Pneumonia, Complicated UTIs)** - **Dose (Traditional)**: **1-2 mg/kg** (ideal body weight or adjusted body weight) - **Frequency**: Every **8 hours** - **Route**: Intravenous (IV) infusion over 30-60 min or Intramuscular (IM) - **Maximum Dose**: Typically **5 mg/kg/day** - **Special considerations**: Therapeutic drug monitoring (TDM) essential for peak/trough levels. **Extended-Interval Dosing (Once-Daily Dosing)** - **Dose**: **4-7 mg/kg** (commonly **5-7 mg/kg** for serious infections) - **Frequency**: Every **24 hours** - **Route**: Intravenous (IV) infusion over 30-60 min - **Special considerations**: Preferred in patients with normal renal function; less frequent monitoring. ### Cystic Fibrosis Pulmonary Exacerbations (IV) - **Dose**: **10-12 mg/kg/day** (often divided into 2-3 doses) or **10-15 mg/kg** once daily. - **Frequency**: Every **8-12 hours** or once daily - **Route**: Intravenous (IV) - **Special considerations**: Higher doses due to altered pharmacokinetics in CF patients. TDM is crucial. ### Dose Adjustments - **Renal Impairment**: Requires significant dose reduction or increased dosing interval. - **CrCl 60-90 mL/min**: Adjust interval (e.g., Q12-24h for traditional). - **CrCl 30-60 mL/min**: Adjust interval (e.g., Q24-48h for traditional). - **CrCl <30 mL/min**: Further interval extension or reduced dose. - **Hemodialysis**: Administer dose after dialysis. - **Hepatic Impairment**: No specific dose adjustment needed. Monitor renal function closely. - **Elderly Patients**: Increased risk of age-related renal decline; monitor renal function frequently. Consider lower doses or extended intervals. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: **2.5 mg/kg** - **Frequency**: Every **12-24 hours** depending on gestational and post-natal age. * Consult institutional guidelines; generally longer intervals for premature or very young neonates. - **Route**: Intravenous (IV) - **Maximum**: Individualize based on TDM and clinical response. - **Special Notes**: Immature renal function necessitates careful dosing and TDM. ### Infants (1-12 months) - **Dose**: **2.5 mg/kg** - **Frequency**: Every **8 hours** (traditional dosing) - **Route**: Intravenous (IV) - **Maximum**: Typically **7.5 mg/kg/day** - **Special Notes**: TDM is highly recommended. ### Children (1-12 years) - **Dose (Systemic)**: **2.5 mg/kg** - **Frequency**: Every **8 hours** (traditional dosing) - **Route**: Intravenous (IV) - **Maximum**: **7.5 mg/kg/day** - **Dose (Cystic Fibrosis)**: **10-12 mg/kg/day** divided Q8-12H, or **10-15 mg/kg** once daily. - **Special Notes**: TDM is essential for all systemic pediatric dosing to optimize therapy and prevent toxicity. ### Adolescents (13-18 years) - **Dose**: Similar to adult dosing. **1-2 mg/kg** Q8h (traditional) or **4-7 mg/kg** Q24h (extended interval). - **Route**: Intravenous (IV) - **Maximum**: **5-7.5 mg/kg/day** (traditional), **7 mg/kg/day** (extended interval). - **Special Notes**: Apply adult dosing guidelines but monitor closely for adverse effects. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to tobramycin or other aminoglycosides. - **Relative**: Pre-existing severe renal impairment, pre-existing hearing loss, myasthenia gravis, Parkinson's disease. ### Common Adverse Effects - **Common (1-10%)**: Nephrotoxicity (reversible acute tubular necrosis), Ototoxicity (vestibular and/or auditory, potentially irreversible), Headache. - **Serious but Rare**: Neuromuscular blockade (respiratory depression, paralysis), Hypersensitivity reactions (rash, anaphylaxis), _Clostridioides difficile_ infection. ### Key Drug Interactions - **Nephrotoxic Agents (e.g., NSAIDs, Cyclosporine, Vancomycin, Amphotericin B)**: Increased risk of nephrotoxicity. Avoid concurrent use or monitor renal function very closely. - **Ototoxic Agents (e.g., Loop Diuretics, Cisplatin)**: Increased risk of ototoxicity. Monitor hearing. - **Neuromuscular Blockers (e.g., Vecuronium, Succinylcholine)**: Potentiates neuromuscular blockade, risking prolonged respiratory depression. Monitor respiratory status. - **Oral Anticoagulants (e.g., Warfarin)**: May enhance anticoagulant effect. Monitor INR. ## Monitoring & Follow-up - **Before Treatment**: Baseline renal function (SCr, BUN, CrCl), electrolytes, hearing assessment (if high risk or prolonged use anticipated). - **During Treatment**: - **Renal Function**: SCr, BUN, urine output daily or every 2-3 days. - **Drug Levels (TDM)**: - **Traditional Dosing**: Peak (30-60 min post-infusion) and Trough (just before next dose). - **Extended-Interval Dosing**: Random level (e.g., 6-14 hours after dose for nomogram). - **Electrolytes**: Potassium, magnesium, calcium (daily or every 2-3 days). - **Clinical Signs**: Monitor for signs of ototoxicity (tinnitus, hearing loss, vertigo, unsteadiness). ## Clinical Pearls - 💡 **Therapeutic Drug Monitoring (TDM)** is critical to ensure efficacy and minimize the risk of nephrotoxicity and ototoxicity, especially with systemic administration. - 💡 **Hydration**: Ensure adequate hydration status to help prevent nephrotoxicity. - 💡 **Nephrotoxicity**: Often dose and duration-dependent; it's typically reversible if detected early and tobramycin is discontinued. - 💡 **Ototoxicity**: Can be irreversible. Counsel patients on potential symptoms (e.g., ringing in ears, dizziness, hearing changes). - 💡 **Formulations**: Differentiate between IV/IM, inhaled, and ophthalmic formulations. Dosing and indications are distinct. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.